Navamedic ASA · OSL:NAVA
Navamedic ASA — Q4 2022 Earnings Presentation
31 slides from Navamedic ASA's earnings presentation, Feb 16, 2023
Slide 1: Fourth quarter 2022 results
Q4 2022 Fourth quarter 2022 results Navamedic ASA 16 February 2023 Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Q4 2022 results
Q4 2022 results Record high revenues Solid growth achieved across the portfolio REVENUE GROSS MARGIN EBITDA Continued strong demand Q4 116.0 MNOK 42.9% 15.7 MNOK for Mysimba® Modifast launched in 2022 Norway Up 29% YoY 41.9% in Q4 21 7.6 MNOK in Q4 21 Innovative antibiotic product acquired for 2022
Slide 3: On track towards 20% organic Y/Y revenue growth target
On track towards 20% organic Y/Y revenue growth target Consistent positive trend in revenue and EBITDA Consistent strong revenue growth over time driven by +37% 400 25% successful build-up of new categories and positive 350 market trends 20% 300 Normal fluctuation in revenue growth between 250 15% q
Slide 4: Navamedic in brief
Navamedic in brief Nordic pharma company targeting growth in Northern Europe A reliable supplier of high- Presence and sales in all Strong local competence Ambitious growth quality pharma products, Nordic countries, Benelux, in regulatory, strategy, high-potential within consumer health, the Baltics
Slide 5: Ambition to build a NOK 1 bn revenue company
Ambition to build a NOK 1 bn revenue company STRATEGY STRENGTHEN THE CORE 1 Untapping the potential within existing products and territories. Ongoing negotiations for attractive new agreements. SECURE AND INCREASE THE VALUE THROUGH 2 OWNERSHIP Innovative pipeline for in-licensing of new RX or OTC, i
Slide 6: High-quality portfolio with several hero products
High-quality portfolio with several hero products MEDICAL NUTRITION SPECIALTY PHARMA CONSUMER HEALTH BRANDED GENERICS Medical nutrition products for Obesity & urology Obesity, gastro, pain & other Antibiotics, cardiology, generics treatment of IEM* 53,9 83% 89,5 4% 42% 27% 159,1 79,6 2022 sales in Y
Slide 7: Medical Nutrition
Medical Nutrition Stable growth continues Q4 2022 REVENUE 14.4 MNOK (Q4 2021: 13.3 MNOK) • The two main areas driving growth in the segment FY 2022 REVENUE • 13% increase in sales of 53.9 MNOK PKU in the quarter (FY 2021: 51.9 MNOK) 7
Slide 8: Branded Generics
Branded Generics Strengthened antibiotic portfolio Q4 2022 REVENUE • Clindamycin bags, an innovative antibiotic 26.2 MNOK product, was acquired in the fourth quarter (Q4 2021: 21.3 MNOK) • Nitrolingual & Forlax contributed to the FY 2022 REVENUE segment 89.5 MNOK • Long-term tenders secured for the
Slide 9: Consumer Health
Consumer Health Obesity and gastro category developing strongly Q4 2022 REVENUE • The Modifast product range 26.3 MNOK was the main contributor to the segment (Q4 2021: 12.6 MNOK) • Increased campaign activities has led to strong FY 2022 REVENUE sales of Thermacare Diaré passer aldri 79.6 MNOK • Alf
Slide 10: Specialty Pharma
Specialty Pharma Growing obesity market CONTINUED STRONG Q4 2022 REVENUE MYSIMBA WHOLESALE DEVELOPMENT 48.9 MNOK 73% grpwth YOY MNOK (Q4 2021: 42.8 MNOK) • Mysimba contributes to 160 obesity market growth 140 120 FY 2022 REVENUE • Urology products 100 80 remains stable 159.1 MNOK 60 40 20 (FY 2021:
Slide 11: Obesity market update
Obesity market update TTL. @ Navamedic THU i
Slide 12: Obesity – a global disease with severe health risks
Obesity – a global disease with severe health risks The challenge • Obesity is an increasingly growing public health challenge which has nearly tripled since 1975 (The WHO) • 13% of the global population suffer from obesity and 1 billion people are estimated to be obese globally by 2030 • In 2020, t
Slide 13: Anti-obesity drugs – the addressable market
Anti-obesity drugs – the addressable market • The global anti-obesity drug market was Development obesity market Nordic valued at UDS 1.9 bn in 2021 at 25% CAGR (in NOK million) • The market is expected to grow from USD 2 200 2.82 bn in 2022 to USD 13.26 bn in 2029 – representing a CAGR of 25% • The
Slide 14: The treatment landscape
The treatment landscape • Obesity remains a significantly undertreated disease Lifestyle • Each patient represents a set of individual needs and intervention not all forms of treatment will be equally effective for all patients • An estimated 1-2% of obesity patients were treated with obesity drugs
Slide 15: Mysimba, a first-in-line treatment for obesity drugs (Norway)
Navamedic’s approach to treating obesity and overweight Mysimba, a first-in-line treatment for obesity drugs (Norway) • Dual mode of action with two active substances that reduce appetite and the amount that patients eat, and increase energy expenditure, helping them to stick to a calorie-controlled
Slide 16: Modifast, lifestyle intervention
Navamedic’s approach to treating obesity and overweight Modifast, lifestyle intervention A range of low-calorie diet (LCD) meals, providing 800- 1200 calories per day if all regular food is replaced Modifast can be used to: • lose weight, • control weigh, or • to lose weight before bariatric surgeri
Slide 17: Seeing the needs of each individual
Navamedic’s approach to treating obesity and overweight Seeing the needs of each individual • Dedicated to meeting each individual patient need, Navamedic has developed MyControl Support – a tailored knowledge and patient support program • Lättare tillsammans (right) – a knowledge-based 6- week prog
Slide 18: Financials
FINANCIALS @ Navamedic
Slide 19: Key consolidated profit and loss figures
Financials Key consolidated profit and loss figures In Q4 2022, revenues grew by 29% compared to the same quarter last (in NOK '1000) Q4 2022 Q4 2021 FY 2022 FY 2021 year and 37% growth for the full year (organic growth was 27%) Operating revenues 115 966 90 160 382 135 278 439 Gross profit 49 762 3
Slide 20: Assets
Financials Assets The increase in Goodwill is mostly due (in NOK '1000) 31.12.2022 31.12.2021 to the Impolin acquisition Goodwill 100 743 61 031 Shares in associated companies is Deferred tax assets 835 9 168 moved to financial assets as Observe Other intangible assets 30 537 27 342 Medical no longe
Slide 21: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 31.12.2022 31.12.2021 Total equity 209 720 151 237 Non-current license liabilities 3 762 8 171 Loans and borrowings 42 539 29 235 Equity ratio of 54.8% Non-current right of use liabilities 4 861 5 824 Total non-current liabilities 51 161 43 231 Total
Slide 22: Cash flow Group – total operations
Financials Cash flow Group – total operations (in NOK '1000) Q4 2022 Q4 2021 Year 2022 Year 2021 The cash flow from Operating Activities Net cash flow from operating activities 19 929 11 284 17 941 -1 300 is mainly the result of Net profit Net cash flow from investing activties 26 -270 -25 444 -727
Slide 23: Summary & Outlook
SUMMARY & OUTLOOK @ Navamedic
Slide 24: Navamedic ASA summary and outlook
Navamedic ASA summary and outlook Strong and scalable foundation in place to become a leading Nordic pharma company TARGETS AND AMBITIONS On track to reach growth target 20% annual organic • Record high NOK 116.0 million revenue in the quarter, an increase of 29% growth Y-o-Y (Q4), underpinned by M&
Slide 25: Q&A
Q&A 25 @ Navamedic
Slide 26: Thank you for your attention!
Thank you for your attention! Navamedic’s Q1 2023 presentation will be held on May 11th, 2023 26
Slide 27: Appendix
APPENDIX @ Navamedic
Slide 28: Condensed consolidated statement of comprehensive income
Navamedic ASA Condensed consolidated statement of comprehensive income (in NOK '1000) Q4 2022 Q4 2021 FY 2022 FY 2021 Operating revenues 115 966 90 160 382 135 278 439 Total revenue 115 966 90 160 382 135 278 439 Cost of materials -66 204 -52 363 -218 615 -166 695 Gross profit 49 762 37 797 163 519
Slide 29: Condensed consolidated statement of cash flows
Navamedic ASA Condensed consolidated statement of cash flows (in NOK '1000) Q4 2022 Q4 2021 Year 2022 Year 2021 Cash flow from operating activities Profit before tax 27 165 1 979 42 506 2 358 Adjusted for: Depreciation, amortization and impairment 1 800 2 564 7 242 6 716 Financial income / expenses
Slide 30: Basis for preparation and Definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 31: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any